Lexicon Pharmaceuticals ( (LXRX) ) has shared an announcement.
Jeffrey L. Wade, the president and chief operating officer of the company, will be leaving his position on September 30, 2024. He will receive a year’s salary continuation, a substantial lump sum, and COBRA payments for health benefits, along with executive outplacement services. Additionally, he’s signed a consulting agreement for eight months post-termination at a monthly fee. Following Wade’s departure, Kristen L. Alexander, with extensive experience in finance and accounting, will step in as the principal financial officer.
For an in-depth examination of LXRX stock, go to TipRanks’ Stock Analysis page.
